Stock Analysis
- United States
- /
- Life Sciences
- /
- NasdaqGS:MRVI
Maravai LifeSciences Holdings First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Maravai LifeSciences Holdings (NASDAQ:MRVI) First Quarter 2024 Results
Key Financial Results
- Revenue: US$64.2m (down 19% from 1Q 2023).
- Net loss: US$12.1m (loss widened by US$12.0m from 1Q 2023).
- US$0.091 loss per share (further deteriorated from US$0.001 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Maravai LifeSciences Holdings Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 5.8%. Earnings per share (EPS) missed analyst estimates by 85%.
Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's shares are up 12% from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Maravai LifeSciences Holdings that you should be aware of before investing here.
Valuation is complex, but we're helping make it simple.
Find out whether Maravai LifeSciences Holdings is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:MRVI
Maravai LifeSciences Holdings
A life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.
Adequate balance sheet and overvalued.